Skip to content
naulon
Not checkedNot checked for notices yet.

Monogenic etiologies in a cohort of early onset obesity: a real-world experience from Belgium

Julie Harvengt, Julie Harvengt, Muriel Hannon and 6 more

Frontiers in Endocrinology · 2025

doi:10.3389/fendo.2025.1608398 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

Introduction Obesity is a major global health issue with multifactorial etiologies. Among them, recent advances in the comprehension of eating and energy regulation showed that around 60 genes involved in the hypothalamic leptin/melanocortin pathway contribute to the development of rare monogenic or syndromic forms of obesity. Objective To better delineate the genetic diagnostic rate and the phenotype in a cohort of early onset obesity and to integrate our results in guidance for genetic testing. Methods In a diagnostic setting, 223 patients with early onset obesity were screened through a targeted panel including 44 genes for severe early onset obesity. Genetic results and clinical descriptions were reviewed for the entire cohort. Results A diagnostic yield of 3.1% was established. Likely pathogenic or pathogenic variants were found in MRAP2 , MC4R , BBS2 , and BBS4 , and a 16p11.2 deletion was confirmed. Clinically, 23% of the cohort had early onset obesity at <1 year, 47% at 1–4 years, and 30% at >4 years. No discriminative clinical feature appears to enhance the diagnostic yield. Thirty-six percent of the cohort presented additional neurological complaints that led to more extensive genetic investigations with a diagnosis rate of 1.8% in this subgroup. Conclusion Our work found a diagnostic yield of 3.1%. Additionally, 19.7% of heterozygous variants of unknown significance were found in genes related to autosomal conditions and 34.9% in genes related to recessive conditions. These results highlight the need for accurate genotype-phenotype correlations. Genetic laboratory expertise in obesity is highly recommended, especially in the context of the availability of new targeted anti-obesity therapies that open the field for current and future perspectives of these targeted genetic investigations.

Abstract licence: CC BY

References34

    34 more references, whose wording the paper’s licence keeps private.

    Reads

    Read by people on this page

    None yet.

    Checked or read by AI through naulon

    None yet.

    A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

    Are you an author?

    Is this your paper?

    Claim it to add your note and be paid when agents cite it. Free.